Search

Naxitamab

[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015.

Carbocromen

Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

Degarelix

Reduction in testosterone is important in treating men with advanced prostate cancer. … Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH.

Profenamine

It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

Trolamine

It is commonly used as a pH adjuster and surfactant in industrial and cosmetic products such as skin and hair conditioning products. … Trolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174].

Trimethadione

An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

Reslizumab

In addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second [L1133]. … Reslizumab is marketed as Cinqaero in Europe.

Gemeprost

It is not FDA-approved but available in Japan marketed as Preglandin. … It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy [A19726].

Cefdinir

It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. … Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.

Potassium sulfate